Citigroup Inc. (C)

Banca diversificada / Servicios financieros

Citigroup is a global systemically important bank with RoTCE of 7.7% (FY2025) on an improving trajectory toward year 5, trading near 52-week highs; the base case values it at 11.0x normalized P/E on net income to common that grows from $13.2 to $20.0 billion, with a limited margin of safety because much of the improvement is already reflected in the price.

Moat Compounder estimates the intrinsic value of Citigroup Inc. (C) at $140 per share on a five-year horizon. With the stock at $137.88 at 2026-09-03 close, the expected total return is 2.7% per year: preserves value. The analysis draws on 10-K FY2025 and 8-K Q2 2026 (results). Analysis dated 2026-08-06.

Price
$137.88
at 2026-09-03 close
Intrinsic value (5y, base)
$140
Total annual return (5y)
2.7%
0.4% price · 2.3% div
Status (nominal)
Preserves value
Margin of safety
No margin

The essentials

  • RoTCE of 7.7% in FY2025, improving to 8.7% annualized in Q2'26, still below the 10% quality bar.
  • Sustained buybacks (-3.5%/year revealed) and a dividend just raised 12%, with a payout of ~92% of the quarter's earnings.
  • Two outstanding regulatory consent orders (FRB and OCC) limit strategic flexibility and sustain an execution-uncertainty premium.
Source 10-K FY2025 Dec 31, 2025 ·8-K Q2 2026 (results) Jul 14, 2026 ·10-Q Q2 2026 Aug 6, 2026 ·DEF 14A 2026 (proxy) Apr 2, 2026
Health: Under watch
Price $138 at 2026-09-03 closeMarket Cap $258.3 bnDeposits $1,403.6 bnP/tangible book 1.4xROTCE 7.7%P/E (today) 19.6x

Intrinsic value — two valuation methods

No margin of safety
Price market
$138
DCF value today
$223
+62.1% vs price
Multiples value today
$126
-8.4% vs price

Total return at 5 years: 2.6%/year = 0.3% appreciation + 2.3% dividend. The target price ($140) is ex-dividend; the $16 in dividends collected over 5 years are added separately.

The methods disagree: one places the value today above the price ($138) and the other below.

Pillars of the analysis

The verdict — today vs 5 years

Today — expensive, no margin of safety: at $138 trades ~9.1% above its value discounted to today (~$126); the expected return does not even reach the risk-free rate (4.5%).

At 5 years — Preserva valor: the target price ($140) plus dividends yield just enough to preserve nominal capital, below the required 4% floor.

The bridge: the return at 5 years falls below the risk-free rate (4.5%) — which is why there is not even a discount to today's value. To require a 15% annual return, it would need to be bought at ~$80.

Thesis

The business

A global systemically important bank with five interconnected businesses and a multi-year transformation program underway. The moat is narrow and stable: regulatory scale protects, but there is no evidence of a widening profitability gap. RoTCE of 7.7% (FY2025) remains below the 10% quality bar, though with a clear improving trajectory in recent periods.

The valuation

Valued as a bank at the equity level: normalized P/E on net income to common projected to year 5, with an exit multiple derived from the 10x-15x band of the bank archetype. The base case uses 11.0x (low-to-mid portion of the band) on net income to common that grows from $13.2 billion today to $20.0 billion at year 5, with the share count falling from sustained buybacks. No margin of safety: at this price capital is preserved, but it is not bought below its value.

The margin of safety

With the stock trading at $134.34, just 8% below its 52-week high, the base case's estimated total return is +3% annually — Preserves value under the method's scale. The margin of safety available today is limited: much of the recent profitability improvement is already reflected in the price.

What to watch

The central disconfirmer is whether RoTCE sustains its improving trajectory (7.0% → 7.7% → 8.7% annualized in Q2'26) beyond an exceptionally strong quarter in Markets, and whether the regulatory consent orders (FRB/OCC) are resolved without additional restrictions on capital allocation. A deterioration in the credit cycle or an adverse CCAR assessment would compress both earnings and the buyback capacity that currently sustains the base case.

Educational / informational. Does not constitute investment advice.

Other companies of the same type